ERBB2 and inflammatory breast carcinoma: Rates of use for HER2-targeting therapies were found to be the highest, regardless of age, with 63.8% of women (all stages) with HER2-positive IBC having a record of receiving trastuzumab or pertuzumab as part of first-line treatment (63.3–64.1% EIBC/LABC; 71.8% MBC).